Kohima News Paper

Thyroid Eye Disease Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

 Breaking News
  • No posts were found

Thyroid Eye Disease Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market

September 26
23:20 2022
Thyroid Eye Disease Market: Analysis of Epidemiology, Pipeline Therapies, and Key Companies Working in the market
Thyroid Eye Disease Market:
DelveInsight’s “Thyroid eye disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Thyroid eye disease, historical and forecasted epidemiology as well as the Thyroid eye disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

DelveInsight’s “Thyroid eye disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Thyroid eye disease, historical and forecasted epidemiology as well as the Thyroid eye disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

 

The Thyroid eye disease market report provides current treatment practices, emerging drugs, Thyroid eye disease market share of the individual therapies, current and forecasted Thyroid eye disease market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Thyroid eye disease treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Thyroid eye disease market.

 

Some of the key facts of the Thyroid eye disease Market Report:

  • According to Abdolreza et al. (2018), the most common clinical complaints of patients at diagnosis of TED were weight loss (35.9%), proptosis (31.1%), and cardiac palpitation (10.7%), with a statistically significant difference in the frequency of clinical complaints between men and women. The most common complaint in men was eye proptosis (42.9%), while in women it was weight loss (37%).

 

Key benefits of the Thyroid eye disease Market report:

 

  • The report covers the descriptive overview of Thyroid eye disease, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Thyroid eye disease epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Thyroid eye disease is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Thyroid eye disease market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Thyroid eye disease market

 

Got queries? Click here to know more about the Thyroid Eye Disease Market Landscape 

Thyroid eye disease Overview

Thyroid eye disease (TED) is a complex orbital inflammatory disease, which can be sight-threatening, debilitating, and disfiguring. TED is also known as Graves ophthalmopathy, named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman presenting with goiter, rapid heartbeat, and exophthalmos.TED affects eye muscles, eyelids, tear glands and fatty tissues behind the eye to become inflamed. This can cause the eyes and eyelids to become red, swollen, and uncomfortable and the eyes can be pushed forward (‘staring’ or ‘bulging’ eyes).

Treatment of TED is based on the signs and symptoms displayed by the patient; there is no “one size fits all” approach. Generally, it is advisable to start with conservative measures, such as ocular lubrication with artificial tears, to manage symptoms of chronic irritation and redness. It is also imperative that the patient be advised to quit smoking because there is a clear link between smoking and disease activity. Medical treatment with systemic oral or pulsed intravenous corticosteroids should be reserved for patients with active inflammation resulting in increased orbital pressure, compressive optic neuropathy, severe periorbital edema, or similar presentations.

The key players are strengthening their market position through strategic mergers, agreements, and acquisitions which is expected to propel the growth of the thyroid eye disease treatment market over the forecasted period (2019-2032). For instance, in May 2017, Horizon Therapeutics acquired the River Vision Development Corp. and its pipeline drug teprotumumab, a human monoclonal antibody for the treatment of thyroid eye disease. This acquisition is expected to cater unmet needs for the treatment of thyroid eye disease.

Thyroid eye disease Epidemiological Insight

 

  • According to Jolene et al. (2020), the overall pooled prevalence of TED was 38% (CI: 0.31 to 0.46) for Europe, 44% (CI: 0.32 to 0.56) for Asia, 27% (CI: 0.06 to 0.56) for North America and 58% (CI: 0.55 to 0.61) for Oceania and in Southeast Asia was 35% (CI: 0.24 to 0.47).
  • According to a study by Bahn et al. (2019), in approximately 40% of patients with TED, the ocular and systemic symptoms have a simultaneous onset.
  • According to Karla et al. (2020), the global prevalence, in patients of thyroid eye disease, was 10.36% for hypothyroidism, 7.9% for euthyroidism, and 86.2% for hyperthyroidism

Thyroid eye disease Market  Epidemiological Segmentation 

  • Thyroid Eye Disease total prevalent cases 
  • Thyroid Eye Disease gender-specific cases 
  • Thyroid Eye Disease age-specific cases
  • Thyroid Eye Disease severity specific cases 

Thyroid eye disease Market Outlook 

The Thyroid eye disease market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Thyroid eye disease market trends by analyzing the impact of current Thyroid eye disease therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

 

This segment gives a thorough detail of Thyroid eye disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Thyroid eye disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the Thyroid eye disease market in 7MM is expected to witness a major change in the study period 2019-2032.

 

Learn more by requesting for sample @Thyroid eye disease Market Landscape

Thyroid eye disease Key Companies  

  •  Viridian Therapeutics
  •  Novartis
  •  Immunovant Sciences Gmb
  • And others

 

Thyroid eye disease  Therapies 

  • VRDN-001
  • Secukinumab
  • IMVT-1401
  • And others

Table of Contents

  •  Key Insights 
  •  Report Introduction 
  •  Executive Summary of Thyroid Eye Disease 
  •  Disease Background and Overview
  •  Epidemiology and patient population
  •  The United States 
  •  EU 5
  •  Thyroid Eye Disease   Emerging Therapies
  •  Thyroid eye disease  Market Outlook
  •   Market Access and Reimbursement of Therapies
  •   Appendix
  •  Thyroid Eye Disease  Report Methodology
  •  DelveInsight Capabilities
  • Disclaimer

Click here to read more about Thyroid eye disease Market 

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/